Medtronic to buy CryoCath for $380M

Medtronic has agreed to acquire CryoCath Technologies for about $380 million, giving the Minneapolis-based Medtronic access to its cryoablation technologies.

The Montreal-based CryoCath board of directors has unanimously recommended that CryoCath shareholders accept the offer, and the acquisition is expected to close in the fourth quarter of this calendar year.

CryoCath said it resolved all outstanding patent suits with Boston Scientific and its units involving cryoablation systems in the U.S. and Canada. The two companies agreed to end an International Trade Commission investigation. CryoCath agreed to pay royalties on certain future products for a limited time.

CryoCath’s flagship product, Arctic Front, is used to treat atrial fibrillation patients.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.